MX2020007731A - Compuestos moduladores de receptor de estrogeno. - Google Patents

Compuestos moduladores de receptor de estrogeno.

Info

Publication number
MX2020007731A
MX2020007731A MX2020007731A MX2020007731A MX2020007731A MX 2020007731 A MX2020007731 A MX 2020007731A MX 2020007731 A MX2020007731 A MX 2020007731A MX 2020007731 A MX2020007731 A MX 2020007731A MX 2020007731 A MX2020007731 A MX 2020007731A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
receptor modulator
compounds
modulator compounds
receptor modulators
Prior art date
Application number
MX2020007731A
Other languages
English (en)
Inventor
Chris Miller
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of MX2020007731A publication Critical patent/MX2020007731A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se describen compuestos que son moduladores de receptor de estrógeno. También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos que se describen en la presente así como métodos de uso de estos moduladores de receptor de estrógeno, solos y en combinación con otros compuestos, para tratar enfermedades o condiciones que son medidas o que dependen de los receptores de estrógeno.
MX2020007731A 2018-01-22 2019-01-22 Compuestos moduladores de receptor de estrogeno. MX2020007731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862620441P 2018-01-22 2018-01-22
PCT/US2019/014581 WO2019144132A1 (en) 2018-01-22 2019-01-22 Estrogen receptor-modulating compounds

Publications (1)

Publication Number Publication Date
MX2020007731A true MX2020007731A (es) 2020-09-25

Family

ID=65352172

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007731A MX2020007731A (es) 2018-01-22 2019-01-22 Compuestos moduladores de receptor de estrogeno.
MX2023000677A MX2023000677A (es) 2018-01-22 2020-07-21 Compuestos moduladores de receptor de estrogeno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000677A MX2023000677A (es) 2018-01-22 2020-07-21 Compuestos moduladores de receptor de estrogeno.

Country Status (13)

Country Link
US (3) US11384068B2 (es)
EP (1) EP3743413A1 (es)
JP (1) JP7288450B2 (es)
KR (1) KR102766460B1 (es)
CN (2) CN119161384A (es)
AU (2) AU2019210129B2 (es)
BR (1) BR112020014746A2 (es)
CA (1) CA3089298A1 (es)
IL (2) IL276152B2 (es)
MA (1) MA51670A (es)
MX (2) MX2020007731A (es)
SG (1) SG11202006942WA (es)
WO (1) WO2019144132A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12428424B2 (en) * 2019-07-22 2025-09-30 Radius Pharmaceuticals, Inc. Estrogen receptor-modulating compounds
JP7680438B2 (ja) 2019-10-01 2025-05-20 サノフイ 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
BR112022009705A2 (pt) 2019-12-09 2022-08-09 Sanofi Sa Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
US12415799B2 (en) * 2020-06-28 2025-09-16 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Indazole-fused cyclic compound
US12595230B2 (en) 2020-10-19 2026-04-07 Sanofi Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
AU2021366223A1 (en) 2020-10-19 2023-06-22 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
CN116615414A (zh) * 2020-10-19 2023-08-18 赛诺菲 经取代的6,7-二氢-5h-苯并[7]轮烯化合物及其衍生物、其制备方法及其治疗用途
TW202313558A (zh) * 2021-07-08 2023-04-01 大陸商勤浩醫藥(蘇州)有限公司 一類苯并七元環類化合物及其應用
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
CN117924262A (zh) * 2022-10-14 2024-04-26 中国科学院上海药物研究所 二氢苯并噻喃类衍生物及其制备方法和用途
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US12558428B2 (en) 2024-03-08 2026-02-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2300857B (en) 1995-05-19 1998-07-08 Pharmacia Spa Indazole [3,2-e] -pyrrole and 1,2,3 -benzotriazole [3,2-e] -pyrrole derivatives
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
ATE295834T1 (de) 1997-08-07 2005-06-15 Lilly Co Eli 1-(4-substituierte alkoxy)benzylnaphthalinderivate als östrogeninhibitoren
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
CZ2004220A3 (cs) * 2001-08-11 2004-06-16 Bristol-Myers Squibb Pharma Company Název neuveden
SI1501819T1 (sl) 2002-04-24 2011-01-31 Merck Sharp & Dohme Modulatorji estrogen receptorjev
CA2571309A1 (en) * 2004-06-22 2006-01-05 Smithkline Beecham Corporation Chemical compounds
SG11201403002RA (en) * 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
HUE039052T2 (hu) * 2013-02-19 2018-12-28 Novartis Ag Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként
WO2014203132A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
EP3303326B1 (en) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
CN108349952A (zh) 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘雌激素受体调节剂及其用途

Also Published As

Publication number Publication date
RU2020123999A (ru) 2022-02-24
KR102766460B1 (ko) 2025-02-11
IL304460B2 (en) 2025-10-01
EP3743413A1 (en) 2020-12-02
IL276152A (en) 2020-09-30
US20240308986A1 (en) 2024-09-19
CN119161384A (zh) 2024-12-20
US12497386B2 (en) 2025-12-16
IL304460A (en) 2023-09-01
AU2023286007A1 (en) 2024-01-25
AU2023286007B2 (en) 2025-04-03
JP7288450B2 (ja) 2023-06-07
CN112105607B (zh) 2024-08-27
US11384068B2 (en) 2022-07-12
US12018019B2 (en) 2024-06-25
SG11202006942WA (en) 2020-08-28
CN112105607A (zh) 2020-12-18
CA3089298A1 (en) 2019-07-25
BR112020014746A2 (pt) 2020-12-08
WO2019144132A1 (en) 2019-07-25
IL276152B2 (en) 2023-12-01
IL276152B1 (en) 2023-08-01
MA51670A (fr) 2020-12-02
AU2019210129A1 (en) 2020-08-13
IL304460B1 (en) 2025-06-01
MX2023000677A (es) 2023-02-13
KR20200113229A (ko) 2020-10-06
AU2019210129B2 (en) 2023-09-28
US20220332704A1 (en) 2022-10-20
JP2021511343A (ja) 2021-05-06
US20200347032A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
MX2015017655A (es) Modulador de receptores de estrogeno y uso del mismo.
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
NZ737399A (en) Ccr2 modulators
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
MX2014011217A (es) Moduladores del receptor de estrogeno y sus usos.
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
UA122868C2 (uk) Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2018011419A (es) Moduladores de receptores estrogénicos.
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
JOP20210330A1 (ar) مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b"
BR112022000855A2 (pt) Moduladores de nlrp3
EA033197B1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
CR20210580A (es) Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
BR112021014566A2 (pt) Moduladores de gpr35
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
BR112017018192A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica.
MX2022011310A (es) Azabiciclo y derivados de diazepina para tratar trastornos oculares.